Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2006 3
2007 2
2008 10
2009 4
2010 9
2011 5
2012 2
2013 4
2014 5
2015 2
2016 1
2017 4
2018 2
2019 11
2020 8
2021 15
2022 5
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Results by year

Filters applied: . Clear all
Page 1
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hollaender N, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F; REACH3 Investigators. Zeiser R, et al. N Engl J Med. 2021 Jul 15;385(3):228-238. doi: 10.1056/NEJMoa2033122. N Engl J Med. 2021. PMID: 34260836 Clinical Trial.
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.
Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, Tocchetti CG, Moslehi JJ, Groarke JD, Bergler-Klein J, Khoo V, Tan LL, Anker MS, von Haehling S, Maack C, Pudil R, Barac A, Thavendiranathan P, Ky B, Neilan TG, Belenkov Y, Rosen SD, Iakobishvili Z, Sverdlov AL, Hajjar LA, Macedo AVS, Manisty C, Ciardiello F, Farmakis D, de Boer RA, Skouri H, Suter TM, Cardinale D, Witteles RM, Fradley MG, Herrmann J, Cornell RF, Wechelaker A, Mauro MJ, Milojkovic D, de Lavallade H, Ruschitzka F, Coats AJS, Seferovic PM, Chioncel O, Thum T, Bauersachs J, Andres MS, Wright DJ, López-Fernández T, Plummer C, Lenihan D. Lyon AR, et al. Among authors: de lavallade h. Eur J Heart Fail. 2020 Nov;22(11):1945-1960. doi: 10.1002/ejhf.1920. Epub 2020 Aug 6. Eur J Heart Fail. 2020. PMID: 32463967 Free PMC article.
Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7).
Cordonnier C, Einarsdottir S, Cesaro S, Di Blasi R, Mikulska M, Rieger C, de Lavallade H, Gallo G, Lehrnbecher T, Engelhard D, Ljungman P; European Conference on Infections in Leukaemia group. Cordonnier C, et al. Among authors: de lavallade h. Lancet Infect Dis. 2019 Jun;19(6):e200-e212. doi: 10.1016/S1473-3099(18)30600-5. Epub 2019 Feb 8. Lancet Infect Dis. 2019. PMID: 30744963 Review.
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial.
Cortes J, Apperley J, Lomaia E, Moiraghi B, Undurraga Sutton M, Pavlovsky C, Chuah C, Sacha T, Lipton JH, Schiffer CA, McCloskey J, Hochhaus A, Rousselot P, Rosti G, de Lavallade H, Turkina A, Rojas C, Arthur CK, Maness L, Talpaz M, Mauro M, Hall T, Lu V, Srivastava S, Deininger M. Cortes J, et al. Among authors: de lavallade h. Blood. 2021 Nov 25;138(21):2042-2050. doi: 10.1182/blood.2021012082. Blood. 2021. PMID: 34407543 Free PMC article. Clinical Trial.
Novel developments in chronic myeloid leukaemia.
Harrington P, de Lavallade H. Harrington P, et al. Among authors: de lavallade h. Curr Opin Hematol. 2021 Mar 1;28(2):122-127. doi: 10.1097/MOH.0000000000000630. Curr Opin Hematol. 2021. PMID: 33464004 Review.
A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia.
Smith G, Apperley J, Milojkovic D, Cross NCP, Foroni L, Byrne J, Goringe A, Rao A, Khorashad J, de Lavallade H, Mead AJ, Osborne W, Plummer C, Jones G, Copland M; British Society for Haematology. Smith G, et al. Among authors: de lavallade h. Br J Haematol. 2020 Oct;191(2):171-193. doi: 10.1111/bjh.16971. Epub 2020 Jul 30. Br J Haematol. 2020. PMID: 32734668 Free article. Review. No abstract available.
Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys).
Okikiolu J, Woodley C, Cadman-Davies L, O'Sullivan J, Radia D, Garcia NC, Harrington P, Kordasti S, Asirvatham S, Sriskandarajah P, Saunders J, Saha C, Sanchez I, deLavallade H, McLornan DP, Harrison CN. Okikiolu J, et al. Leuk Res Rep. 2022 Dec 16;19:100360. doi: 10.1016/j.lrr.2022.100360. eCollection 2023. Leuk Res Rep. 2022. PMID: 36590864 Free PMC article.
82 results